Table 1 Patient demographics and tumor characteristics
Primary localized | Recurred localized | Metastatic | Overall | |
|---|---|---|---|---|
Number of patients | 9 | 13 | 15 | 37 (100) |
Median age at operation | 59.0 (22–73) | 59.0 (25–75) | 39.0 (19–72) | 54.0 (19–75) |
Male: female ratio | 0.80 (4:5) | 2.25 (9:4) | 1.46 (9:6) | 1.46 (22:15) |
Level of amputation | ||||
Upper limb | ||||
Total | 3 (33.3) | 10 (76.9) | 4 (26.7) | 17 (46.0) |
Below elbow | 1 (11.1) | 4 (30.8) | 0 (0) | 5 (13.5) |
Above elbow | 1 (11.1) | 5 (38.5) | 3 (20.0)) | 9 (24.3) |
Shoulder disarticulation | 1 (11.1) | 1 (7.7) | 0 (0) | 2 (5.4) |
Forequarter | 0 (0) | 0 (0) | 1 (6.7) | 1 (2.7) |
Lower limb | ||||
Total | 6 (66.6) | 3 (23.1) | 11 (73.3) | 20 (54.0) |
Below foot | 2 (22.2) | 0 (0) | 0 (0) | 2 (5.4) |
Below knee | 3 (33.3) | 2 (15.4) | 5 (33.3) | 10 (27.0) |
Above knee | 1 (11.1) | 1 (7.7) | 5 (33.3) | 7 (18.9) |
Hindquarter | 0 (0) | 0 (0) | 1 (6.7) | 1 (2.7) |
Median tumor size | 4.80 (1–18) | 4.85 (1–20) | 7.00 (2–26) | 6.40 (1–26) |
Histological subtype | ||||
Myxofibrosarcoma | 2 (22.2) | 3 (23.1) | 0 (0) | 5 (13.5) |
Undifferentiated pleomorphic sarcoma | 1 (11.1) | 6 (46.2) | 5 (33.3) | 12 (32.4) |
Liposarcoma | 1 (11.1) | 1 (7.7) | 0 (0) | 2 (5.4) |
Synovial sarcoma | 1 (11.1) | 0 (0) | 2 (13.3) | 3 (8.1) |
Leiomyosarcoma | 0 (0) | 1 (7.7) | 0 (0) | 1 (2.7) |
Rhabdomyosarcoma | 0 (0) | 0 (0) | 2 (13.3) | 2 (5.4) |
Epitheliod sarcoma | 2 (22.2) | 2 (15.4) | 1 (6.7) | 5 (13.5) |
Clear cell sarcoma | 0 (0) | 0 (0) | 3 (20.0) | 3 (8.1) |
Malignant hemangiopericytoma | 1 (11.1) | 0 (0) | 0 (0) | 1 (2.7) |
Malignant peripheral nerve sheath tumor | 1 (11.1) | 0 (0) | 0 (0) | 1 (2.7) |
Extraskeletal osteosarcoma | 0 (0) | 0 (0) | 2 (13.3) | 2 (5.4) |
Histologic grade (FNCLCC) | ||||
Grade 1 | 1 (11.1) | 0 (0) | 0 (0) | 1 (2.7) |
Grade 2 | 2 (22.2) | 8 (61.5) | 2 (13.3) | 12 (32.4) |
Grade 3 | 4 (44.4) | 2 (15.4) | 13 (86.7) | 19 (51.4) |
Unknown | 2 (22.2) | 3 (23.1) | 0 (0) | 5 (13.5) |
Depth | ||||
Deep | 9 (100) | 12 (92.3) | 14 (93.3) | 35 (94.6) |
Superficial | 0 (0) | 1 (7.7) | 1 (6.7) | 2 (5.4) |
Pathologic margin | ||||
Negative margin | 9 (100) | 11 (84.6) | 14 (93.3) | 34 (91.9) |
Positive margin | 0 (0) | 2 (15.4) | 1 (6.7) | 3 (8.1) |
Adjuvant treatment | ||||
Preoperative radiotherapy | 0 (0) | 4 (30.8) | 0 (0) | 4 (10.8) |
Postoperative radiotherapy | 1 (11.1) | 7 (53.9) | 5 (33.3) | 13 (35.1) |
Preoperative chemotherapy | 1 (11.1) | 1 (7.7) | 0 (0) | 2 (5.4) |
Postoperative chemotherapy | 2 (22.2) | 2 (15.4) | 7 (46.7) | 11 (29.7) |